Supplemental Figure 1 from Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma

Authors:

Abstract
Plasma cytokine levels of LTCR responders compared to all other patients.